![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Funding will help advance Gliknik clinical and pre-clinical programs, including: A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion.
Lead Product(s): Biropepimut-S,GM CSF,Cyclophosphamide
Therapeutic Area: Oncology Product Name: GL-0817
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: First In Ventures
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 24, 2021